Investing.com - Wolfe Research initiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Peerperform rating on Sunday, assigning a fair value range of $40 to $65 per share.
The firm’s valuation framework combines a long-term discounted cash flow model and a sum-of-the-parts analysis that separately values the Diagnostics and Data & Services businesses. The DCF model projects Oncology, Hereditary, and Data & Services segments over a 15-plus year period to terminal growth.
Tempus has established itself as the second-largest player in therapy selection with approximately 30% of the tissue testing market and roughly 25% of the liquid testing market, according to Wolfe’s market modeling. Following a sales force expansion in 2024, the company has grown its testing volumes ahead of the broader therapy selection market. The company posted impressive revenue growth of 69.8% over the last twelve months, though InvestingPro Tips note the company remains unprofitable with analysts not expecting profitability this year.
Wolfe projects Data & Services revenue growth exceeding 20% over the next few years, below Tempus’s stated goal of 25%-plus growth for the data business over the mid-term. The firm models long-term EBIT margin reaching the mid-30% range.
Applying a 3.5% terminal growth rate and a 10.5% discount rate yields a valuation of approximately $45. Wolfe frames fair value using a range of discount rates at 9.5% plus or minus 1%. Wall Street analysts have set price targets ranging from $35 to $100, with InvestingPro analysis suggesting the stock may be overvalued at current levels. For deeper insights, investors can access TEM’s comprehensive Pro Research Report, one of 1,400+ available reports transforming complex data into actionable intelligence.
In other recent news, Tempus AI, Inc. has reported several significant developments. The company announced that the U.S. Food and Drug Administration approved a tumor-only indication for its xT CDx next-generation sequencing platform. This approval allows the test to function without a patient’s matched normal sample, making Tempus the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. Additionally, Tempus presented results from its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting. These models were trained on a substantial dataset, including millions of clinical notes, medical images, and genomic sequences. The company also expanded its AI platform to cover six new cancer types, enhancing its Next platform to include scenarios for breast, colorectal, ovarian, prostate, and urothelial cancers. This expansion was highlighted in a study involving early-stage non-small cell lung cancer patients. These recent developments showcase Tempus AI’s ongoing advancements in the field of clinical oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.